YU13902A - Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene - Google Patents

Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene

Info

Publication number
YU13902A
YU13902A YU13902A YUP13902A YU13902A YU 13902 A YU13902 A YU 13902A YU 13902 A YU13902 A YU 13902A YU P13902 A YUP13902 A YU P13902A YU 13902 A YU13902 A YU 13902A
Authority
YU
Yugoslavia
Prior art keywords
mesoprogestins
female
progesterone receptor
component
contraception
Prior art date
Application number
YU13902A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU13902A publication Critical patent/YU13902A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YU13902A 1999-08-31 2000-08-31 Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene YU13902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
YU13902A true YU13902A (sh) 2006-01-16

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
YU13902A YU13902A (sh) 1999-08-31 2000-08-31 Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene

Country Status (28)

Country Link
EP (1) EP1605949A2 (fr)
JP (1) JP2003511399A (fr)
KR (1) KR20020038745A (fr)
CN (1) CN1384748A (fr)
AR (1) AR025455A1 (fr)
AU (1) AU781835B2 (fr)
BG (1) BG106441A (fr)
BR (1) BR0013711A (fr)
CA (1) CA2383650A1 (fr)
CO (1) CO5190694A1 (fr)
CZ (1) CZ2002707A3 (fr)
EA (1) EA006805B1 (fr)
EE (1) EE200200103A (fr)
HR (1) HRP20020265A2 (fr)
HU (1) HUP0202515A3 (fr)
IL (1) IL148415A0 (fr)
LT (1) LT5001B (fr)
LV (1) LV12940B (fr)
MX (1) MXPA02002186A (fr)
NO (1) NO20020998L (fr)
NZ (1) NZ517470A (fr)
PE (1) PE20010579A1 (fr)
PL (1) PL353994A1 (fr)
SI (1) SI20853A (fr)
SK (1) SK2982002A3 (fr)
UA (1) UA77150C2 (fr)
WO (1) WO2001026603A2 (fr)
YU (1) YU13902A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014935A1 (fr) * 2002-08-02 2004-02-19 Schering Aktiengesellschaft Modulateurs de recepteurs de progesterone presentant une activite antigonadotrope augmentee, destines au controle de fertilite et au traitement hormonal substitutif chez la femme
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
CN104208067A (zh) * 2004-07-07 2014-12-17 惠氏公司 周期性黄体酮方案及试剂盒
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
EP3106167A1 (fr) 2009-04-14 2016-12-21 Laboratoire HRA Pharma Procédé de contraception à la demande
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
EP0559240B1 (fr) * 1987-09-24 2001-12-05 Jencap Research Limited Packages contraceptives contenant de l'estrogen et du progestin
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0787002B1 (fr) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Antagonistes competitifs de la progesterone permettant de reguler a la demande la fecondite feminine
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
PL330916A1 (en) * 1996-06-25 1999-06-07 Akzo Nobel Nv Progestagen-antiprogestagen dosing schemes
WO1998005679A2 (fr) * 1996-08-05 1998-02-12 Duke University Antagonistes mixtes du recepteur progesterone et techniques de dosage associees
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000066590A2 (fr) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes

Also Published As

Publication number Publication date
IL148415A0 (en) 2002-09-12
AU3215001A (en) 2001-04-23
EE200200103A (et) 2003-04-15
HUP0202515A2 (hu) 2002-12-28
WO2001026603A2 (fr) 2001-04-19
JP2003511399A (ja) 2003-03-25
PE20010579A1 (es) 2001-06-04
KR20020038745A (ko) 2002-05-23
PL353994A1 (en) 2003-12-15
AR025455A1 (es) 2002-11-27
NO20020998D0 (no) 2002-02-28
UA77150C2 (en) 2006-11-15
LT5001B (lt) 2003-03-25
NO20020998L (no) 2002-03-14
EA006805B1 (ru) 2006-04-28
SI20853A (sl) 2002-10-31
HUP0202515A3 (en) 2004-06-28
CZ2002707A3 (cs) 2002-11-13
SK2982002A3 (en) 2002-07-02
CN1384748A (zh) 2002-12-11
BR0013711A (pt) 2002-05-07
MXPA02002186A (es) 2002-09-02
EP1605949A2 (fr) 2005-12-21
CA2383650A1 (fr) 2001-04-19
LT2002035A (lt) 2002-10-25
HRP20020265A2 (en) 2004-02-29
CO5190694A1 (es) 2002-08-29
AU781835B2 (en) 2005-06-16
BG106441A (bg) 2002-09-30
EA200200284A1 (ru) 2002-10-31
WO2001026603A3 (fr) 2002-01-17
NZ517470A (en) 2004-03-26
LV12940B (en) 2003-06-20

Similar Documents

Publication Publication Date Title
WO1995011013A3 (fr) Combinaison d'antagonistes de la progesterone et d'anti-×strogenes a action partiellement agoniste pour l'hormonotherapie substitutive des femmes peri et postmenopausees
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2002047693A3 (fr) Produits a base d'hormone steroide et leurs procedes de fabrication
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
WO2000066590A3 (fr) Composes modulateurs de recepteur de progesterone tetracycliques et procedes
CA2222133A1 (fr) Timbre transdermique et procede d'administration de 17-deacetyl norgestimate, seul ou en combinaison avec un oestrogene
HUP0104037A3 (en) Drug delivery device, especially for the delivery of progestins and estrogens
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
MY152750A (en) Transdermal delivery system of hormones without penetration enhancers
YU13902A (sh) Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
WO2000074649A3 (fr) Compositions ophtalmiques a base d'histamine et leurs utilisations
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1090639A3 (fr) Composition pharmaceutique contenant un corticoide progestatif et un modulateur sélectif du récepteur oestrogénique
WO2001015679A3 (fr) Mesoprogestines (modulateurs du recepteur de la progesterone) pour le traitement et la prevention de troubles gynecologiques hormonodependants benins
WO1999020223A3 (fr) Antagonistes de l'hormone luteinisante utiles pour le traitement de carences oestrogeniques ou utilises en tant que contraceptif
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
WO2001034126A3 (fr) Mesoprogestines (modulateurs des recepteurs de progesterone) utilises comme composants de compositions de traitement hormonal substitutif
MXPA01011296A (es) Composiciones contraceptivas que contienen derivados de indolina y agentes progestacionales.
WO2003099322A3 (fr) Derives d'il-11 et leurs utilisations therapeutiques
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
WO1996028154A3 (fr) Utilisation d'anti-oestrogenes comme contraceptifs masculins
BR0116127A (pt) Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina
AU1901401A (en) Condom set for preventing premature ejaculation